Practical guidance on the use of sacubitril/valsartan for heart failure

Sacubitril/valsartan

(2018) Edoardo Sciatti et al.   Journal of Cardiovascular Medicine

Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction

(2017) Nancy Luo et al.   JACC-Heart Failure

Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril

(2017) Akshay S. Desai et al.   JAMA Cardiology

Sacubitril–Valsartan in Heart Failure: Why Are More Physicians Not Prescribing It?

(2016) Milton Packer et al.   ANNALS OF INTERNAL MEDICINE

Cost-Effectiveness of Sacubitril–Valsartan in Patients With Heart Failure With Reduced Ejection Fraction

(2016) Alexander T. Sandhu et al.   ANNALS OF INTERNAL MEDICINE

The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects

(2016) Thomas H. Langenickel et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF TrialCLINICAL PERSPECTIVE

(2016) Akshay S. Desai et al.   Circulation-Heart Failure

Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background TherapyCLINICAL PERSPECTIVE

(2016) Naoki Okumura et al.   Circulation-Heart Failure

Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial

(2016) Orly Vardeny et al.   EUROPEAN JOURNAL OF HEART FAILURE

Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens

(2016) Michele Senni et al.   EUROPEAN JOURNAL OF HEART FAILURE

Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction

(2016) Jane A. Cannon et al.   EUROPEAN JOURNAL OF HEART FAILURE

Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization

(2016) Akshay S. Desai et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure

(2016) Clyde W. Yancy et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Sacubitril-Valsartan for the Treatment of Heart Failure

(2016) Daniel A. Ollendorf et al.   JAMA Internal Medicine

Love of Angiotensin-Converting Enzyme Inhibitors in the Time of Cholera

(2016) Milton Packer   JACC-Heart Failure

Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation

(2016) Scott D. Solomon et al.   JACC-Heart Failure

Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction

(2016) Thomas A. Gaziano et al.   JAMA Cardiology

Potential Mortality Reduction With Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure

(2016) Gregg C. Fonarow et al.   JAMA Cardiology

Heart Disease and Stroke Statistics—2016 Update

(2015) Dariush Mozaffarian et al.   CIRCULATION

Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF

(2015) Pardeep S. Jhund et al.   EUROPEAN HEART JOURNAL

Estimating the Long-Term Treatment Benefits of Sacubitril–Valsartan

(2015) Brian Claggett et al.   NEW ENGLAND JOURNAL OF MEDICINE

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

(2014) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Neprilysin and Renin-Angiotensin System Inhibition for the Treatment of Heart Failure

(2014) Orly Vardeny et al.   JACC-Heart Failure

2013 ACCF/AHA Guideline for the Management of Heart Failure

(2013) Clyde W. Yancy et al.   CIRCULATION

Length of delay in seeking medical care by patients with heart failure symptoms and the role of symptom-related factors: a narrative review

(2010) Shannon Gravely-Witte et al.   EUROPEAN JOURNAL OF HEART FAILURE

Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi)

(2009) Jessie Gu et al.   JOURNAL OF CLINICAL PHARMACOLOGY